The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...

After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

Medtronic, the largest medical device maker in the world, said it contained a cyberattack on its corporate IT systems and ...

After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to ...

Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...

After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...

Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech that no deals ...